A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Phase 2
70
about 3.9 years
18+
39 sites in AL, AZ, CA +16
What this study is about
This trial is testing a treatment called EIK1001 when combined with pembrolizumab and chemotherapy for people with advanced lung cancer. The goal is to see if this combination is safe, well-tolerated, and effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Carboplatin
- 2.Take EIK1001
- 3.Take Paclitaxel
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
carboplatin, paclitaxel (Taxane chemotherapy; stabilizes microtubules), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), pemetrexed
injection, intravenous, infusion, injection (Injection)
Secondary: Percentage of participants with objective response rate (ORR) and duration of response (DOR).
Oncology